Clinical Trial Update: Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576 [Phase 3]

View source ↗

Summary

This Clinical Trials update notes completion of a Phase 3 study of rVA576 for treating paroxysmal nocturnal hemoglobinuria (PNH).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• rVA576 (rVA576)

Snippet

Sponsor: AKARI Therapeutics | Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 3 | Status: COMPLETED